Laurion Capital Management LP bought a new stake in Radius Health Inc (NASDAQ:RDUS) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 146,643 shares of the biopharmaceutical company’s stock, valued at approximately $2,610,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. BB Biotech AG grew its position in shares of Radius Health by 6.3% in the third quarter. BB Biotech AG now owns 6,590,276 shares of the biopharmaceutical company’s stock valued at $117,307,000 after purchasing an additional 389,363 shares during the period. Voya Investment Management LLC grew its position in shares of Radius Health by 4.3% in the second quarter. Voya Investment Management LLC now owns 731,818 shares of the biopharmaceutical company’s stock valued at $21,567,000 after purchasing an additional 30,003 shares during the period. Northern Trust Corp grew its position in shares of Radius Health by 10.1% in the second quarter. Northern Trust Corp now owns 480,107 shares of the biopharmaceutical company’s stock valued at $14,149,000 after purchasing an additional 44,104 shares during the period. Bank of America Corp DE grew its position in shares of Radius Health by 22.3% in the second quarter. Bank of America Corp DE now owns 413,991 shares of the biopharmaceutical company’s stock valued at $12,201,000 after purchasing an additional 75,462 shares during the period. Finally, Candriam Luxembourg S.C.A. grew its position in shares of Radius Health by 8.4% in the third quarter. Candriam Luxembourg S.C.A. now owns 304,025 shares of the biopharmaceutical company’s stock valued at $5,412,000 after purchasing an additional 23,500 shares during the period.
NASDAQ:RDUS opened at $15.84 on Friday. The company has a current ratio of 5.50, a quick ratio of 5.39 and a debt-to-equity ratio of 1.85. Radius Health Inc has a twelve month low of $14.52 and a twelve month high of $41.16.
Radius Health (NASDAQ:RDUS) last posted its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.26) by $0.17. The firm had revenue of $27.70 million for the quarter, compared to the consensus estimate of $26.00 million. Radius Health had a negative net margin of 346.67% and a negative return on equity of 140.79%. The company’s revenue for the quarter was up 105.2% on a year-over-year basis. During the same period last year, the firm posted ($1.31) earnings per share. As a group, equities research analysts anticipate that Radius Health Inc will post -5.17 earnings per share for the current fiscal year.
RDUS has been the topic of several research reports. BidaskClub raised shares of Radius Health from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 2nd. Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. Cowen reissued a “hold” rating on shares of Radius Health in a research note on Thursday, October 18th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Radius Health from $59.00 to $52.00 and set an “overweight” rating on the stock in a research note on Friday, November 2nd. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $44.38.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/12/08/146643-shares-in-radius-health-inc-rdus-acquired-by-laurion-capital-management-lp.html.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.
Featured Story: Consumer Price Index (CPI)
Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health Inc (NASDAQ:RDUS).
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.